MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
暂无分享,去创建一个
T. Golub | W. Hahn | B. Weir | L. Garraway | D. Root | J. Boehm | G. Kryukov | J. Bradner | F. Vazquez | G. Cowley | Aviad Tsherniak | C. Clish | F. H. Wilson | C. Bielski | J. Ruth | C. Dennis | Joshiawa Paulk | M. Fitzgerald | Minoru Tanaka | Sara E Marlow | Justin Scott
[1] Konstantinos J. Mavrakis,et al. Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5 , 2016 .
[2] Konstantinos J. Mavrakis,et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.
[3] Pierre-Jacques Hamard,et al. Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. , 2015, The Journal of clinical investigation.
[4] Robert A Copeland,et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.
[5] C. Koh,et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis , 2015, Nature.
[6] D. Choi,et al. PRMT5 is essential for the eIF4E-mediated 5'-cap dependent translation. , 2014, Biochemical and biophysical research communications.
[7] Ellen T. Gelfand,et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.
[8] J. Bertino,et al. 6-thioguanine: a drug with unrealized potential for cancer therapy. , 2014, The oncologist.
[9] K. Howitz,et al. Assay development for histone methyltransferases. , 2013, Assay and drug development technologies.
[10] M. Bedford,et al. Protein arginine methyltransferases and cancer , 2012, Nature Reviews Cancer.
[11] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[12] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[13] Randall W. King,et al. A Bioinformatics Method Identifies Prominent Off-targeted Transcripts in RNAi Screens , 2012, Nature Methods.
[14] Yu-Jie Hu,et al. Versatility of PRMT5-induced methylation in growth control and development. , 2011, Trends in biochemical sciences.
[15] J. Mesirov,et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.
[16] J. Bertino,et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity , 2011, Cancer biology & therapy.
[17] A. Sickmann,et al. RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity* , 2010, The Journal of Biological Chemistry.
[18] Xinbin Chen,et al. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function , 2009, Nucleic acids research.
[19] Robert L Moritz,et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing , 2009, Nature Structural &Molecular Biology.
[20] H. Burris,et al. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer , 2009, Investigational New Drugs.
[21] L. Lim,et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.
[22] J. Eshleman,et al. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers , 2005, Molecular Cancer Therapeutics.
[23] E. Montgomery,et al. Concordant Loss of MTAP and p16/CDKN2A Expression in Gastroesophageal Carcinogenesis: Evidence of Homozygous Deletion in Esophageal Noninvasive Precursor Lesions and Therapeutic Implications , 2005, The American journal of surgical pathology.
[24] Mark T Bedford,et al. Arginine methylation an emerging regulator of protein function. , 2005, Molecular cell.
[25] J. Cameron,et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: A potential new target for therapy , 2005, Cancer biology & therapy.
[26] M. Ladanyi,et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] P. Diegelman,et al. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. , 2002, Cancer research.
[28] M. Mann,et al. A Novel WD Repeat Protein Component of the Methylosome Binds Sm Proteins* , 2002, The Journal of Biological Chemistry.
[29] Juri Rappsilber,et al. The Methylosome, a 20S Complex Containing JBP1 and pICln, Produces Dimethylarginine-Modified Sm Proteins , 2001, Molecular and Cellular Biology.
[30] Steven Clarke,et al. PRMT5 (Janus Kinase-binding Protein 1) Catalyzes the Formation of Symmetric Dimethylarginine Residues in Proteins* , 2001, The Journal of Biological Chemistry.
[31] S. Pestka,et al. The Human Homologue of the Yeast Proteins Skb1 and Hsl7p Interacts with Jak Kinases and Contains Protein Methyltransferase Activity* , 1999, The Journal of Biological Chemistry.
[32] P. Tran,et al. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Savarese,et al. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. , 1996, Cancer research.
[34] J. Seidenfeld,et al. Trends in the biochemical pharmacology of 5'-deoxy-5'-methylthioadenosine. , 1982, Biochemical pharmacology.